ME

MEDIPOSTCO.,LTD.

Develops stem cell therapeutics and regenerative medicine for incurable diseases.

078160 | KO

Overview

Corporate Details

ISIN(s):
KR7078160009
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로 644번길21 -, 성남시

Description

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-04-15 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.9 KB
2022-04-15 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2022-04-08 00:00
증권발행결과(자율공시)
Korean 6.0 KB
2022-04-08 00:00
주식등의대량보유상황보고서(일반)
Korean 149.8 KB
2022-03-31 00:00
주식등의대량보유상황보고서(일반)
Korean 73.4 KB
2022-03-30 00:00
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 14.0 KB
2022-03-30 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.1 KB
2022-03-29 00:00
정기주주총회결과
Korean 30.4 KB
2022-03-29 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.3 KB
2022-03-28 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 74.7 KB
2022-03-28 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 82.4 KB
2022-03-28 00:00
증권발행결과(자율공시)
Korean 6.0 KB
2022-03-28 00:00
주식등의대량보유상황보고서(일반)
Korean 144.7 KB
2022-03-21 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 305.6 KB
2022-03-21 00:00
[기재정정]경영권변경등에관한계약체결
Korean 38.9 KB

Automate Your Workflow. Get a real-time feed of all MEDIPOSTCO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MEDIPOSTCO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MEDIPOSTCO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.